Filing Flows › Adma Biologics (ADMA) › Gross margin
Adma Biologics (ADMA) gross margin by quarter
Adma Biologics' gross margin was 70.8% in Q3 2026 (third quarter 2026), +1.5 pts from Q2 2026. Over the last 7 quarters it ranged from 53.2% (Q1 2025) to 70.8% (Q3 2026).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 70.8% | +1.5 pts | +14.5 pts |
| Q2 2026 | 69.4% | -1.2 pts | +14.2 pts |
| Q1 2026 | 70.5% | +6.7 pts | +17.3 pts |
| Q4 2025 | 63.8% | +7.5 pts | — |
| Q3 2025 | 56.3% | +1.2 pts | — |
| Q2 2025 | 55.1% | +1.9 pts | — |
| Q1 2025 | 53.2% | — | — |
Q3 2026 at a glance
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Adma Biologics' gross margin?
Adma Biologics' gross margin was 70.8% in Q3 2026 (third quarter 2026), +1.5 pts from Q2 2026.
How has Adma Biologics' gross margin changed?
Over the last 7 quarters it ranged from 53.2% (Q1 2025) to 70.8% (Q3 2026).